Metabolite Panel for Non-Invasive Colorectal Cancer Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current non-invasive methods for detecting colorectal cancer or adenoma suffer from low accuracy, and invasive methods cause discomfort and tissue damage, necessitating the development of more accurate biomarkers for early diagnosis.

Innovation Solution

A panel of diagnostic biomarkers, including specific metabolites listed in Tables A, B, and C, is used to quantify and process sample scores for effective detection of colorectal cancer or adenoma through a method involving mass spectrometry and logistic regression, achieving high sensitivity and specificity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If non-invasive approaches (FOBT, CEA) are used for CRC detection, then patient comfort is improved, but detection accuracy deteriorates

Engineering Contradiction:

Improvepatient comfortVSAvoiddetection accuracy

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent segments the detection process by dividing the complex metabolic profile into multiple specific metabolite markers (Table A metabolites) that can be individually quantified. This segmentation allows for more precise measurement of specific cancer-related metabolic changes while maintaining the non-invasive nature of the test.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent changes the detection parameter from general tumor markers (CEA) to a panel of specific metabolite abundance ratios. By measuring and comparing the abundance of multiple specific metabolites (e.g., metabolite A/metabolite B ratios), the detection accuracy is significantly improved while maintaining patient comfort.

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If invasive approaches (colonoscope, biopsy) are used for CRC detection, then detection accuracy is improved, but patient discomfort and tissue damage increase

Engineering Contradiction:

Improvedetection accuracyVSAvoidpatient discomfort and tissue damage

Core Design Contradiction:

Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The patent uses metabolites in body fluids (blood, urine, or other biofluids) as intermediary markers that reflect the presence of colorectal cancer or adenoma. These metabolite markers serve as intermediaries between the disease state and the detection method, allowing accurate diagnosis without direct visualization or tissue sampling.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical invasive procedures (colonoscopy, biopsy) with a chemical/biochemical detection system that measures metabolite abundances. This substitution eliminates the need for physical insertion of instruments into the colon, thereby eliminating patient discomfort and tissue damage while maintaining high detection accuracy.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Ease of operation

If conventional non-invasive approaches are used, then patient comfort is maintained, but early-stage detection capability deteriorates

Engineering Contradiction:

Improvepatient comfortVSAvoidearly-stage detection capability

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent enables preliminary detection of colorectal cancer or adenoma by measuring specific metabolite profiles that change early in the disease process. The metabolite abundance ratios serve as early warning markers that can detect the presence of adenoma or early-stage cancer before symptoms appear, allowing for early intervention while maintaining patient comfort.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method provides a non-invasive, accurate means of detecting colorectal cancer or adenoma, improving patient outcomes by enhancing early-stage detection and distinguishing between normal and affected subjects with high sensitivity and specificity.

Implementation Method 1

a method of detecting CRC/CRA in a subject is provided. In some embodiments, the method may include step a) quantifying the abundance of one or more components of a panel of a plurality of metabolites in a sample from the subject

Methodology Applied

Scientific EffectMass spectrometry:

Data Source

PatentUS11462305B2Biomarkers for detecting colorectal cancer or adenoma and methods thereof

Publication Date: 2022.10.04 PRECOGIFY PHARM CHINA CO LTD

AI summary

The present disclosure provides a group of diagnostic biomarkers usable for diagnosis of colorectal cancer or colorectal adenoma. A method for detecting colorectal cancer or colorectal adenoma using the group of diagnostic biomarkers is also provided. For example, the method provided by the present disclosure is a non-invasive approach that may utilize serum samples for detecting colorectal cancer. Moreover, the method for detecting colorectal cancer may detect colorectal cancer of different stages (e.g., pre-cancer stage, early stage, middle stage, late stage).